Another ongoing phase II study will investigate the combination of immunotherapy with E75 and trastuzumab to prevent recurrence among high-risk HER2-positive breast cancer patients who are disease-free after standard of care therapy. This evidence concerns the gene ERBB2 and breast carcinoma.